Evidence map›Paper›PMID 40130882›Full record

ArticleJournal of clinical microbiology2025

Impact of media brand on cefiderocol disk diffusion results.

M G DeMarco, A M Field, L E Donohue, H L Cox, T S Kidd, K E Barry, A J Mathers

Abstract read
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. AMRrounds: Metallo-β-lactamase-producingJAC-antimicrobial resistance · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

M G DeMarco *Department of Pharmacy Services, University of Virginia Health, Charlottesville, Virginia, USA.ORCID 0000-0003-2658-6495
A M Field *Department of Pharmacy Services, University of Virginia Health, Charlottesville, Virginia, USA.ORCID 0000-0002-1268-1814
L E DonohueDepartment of Pharmacy Services, University of Virginia Health, Charlottesville, Virginia, USA.
H L CoxDepartment of Pharmacy Services, University of Virginia Health, Charlottesville, Virginia, USA.
T S KiddClinical Microbiology, University of Virginia Health, Charlottesville, Virginia, USA.
K E BarryDivision of Infectious Diseases and International Health, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
A J MathersDivision of Infectious Diseases and International Health, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0002-3533-6351

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cefiderocol is a siderophore cephalosporin that utilizes iron transport systems to cross cell membranes. This unique strategy complicates antimicrobial susceptibility testing (AST) due to variable iron content in media. While guidance for using iron-depleted media exists for broth microdilution (BMD), disk diffusion (DD) with commercial media is a common AST method in the clinical laboratory. We investigated cefiderocol DD result variability using multiple Mueller-Hinton agar (MHA) brands. DD results using Remel (Thermo Fisher Scientific, San Diego, CA), Hardy (Hardy Diagnostics, Springboro, OH), and BBL (Becton Dickinson, East Rutherford, NJ) MHA were compared to those of BMD using iron-depleted cation-adjusted Mueller-Hinton broth. BMD reproducibility, BMD trailing endpoints, and DD intra- and inter-brand variability in zones of inhibition were investigated. Forty-seven multidrug-resistant clinical isolates and three Antibiotic Resistance Bank isolates composed of IMPORTANCE: The novel mechanism of action of cefiderocol overcomes a variety of resistance mechanisms associated with gram-negative bacteria and positions the agent as an attractive option for treating infections involving multidrug-resistant pathogens. The availability of accurate, timely antimicrobial susceptibility testing methods for cefiderocol in clinical microbiology laboratories is critical as cefiderocol-resistant isolates have been described and may contribute to treatment failure. Iron-depleted broth microdilution testing may not be feasible for use in many clinical laboratories. While disk diffusion is an appealing, practical method to implement, our data demonstrate reproducibility issues across agar brands, most notably for organisms that do not test susceptible to cefiderocol when using broth microdilution. Discrepancy errors and misclassifications of resistant isolates as susceptible, and susceptible isolates as resistant, may mislead clinicians and compromise the treatment efficacy. More work is needed to standardize practical yet reproducible methods for cefiderocol antimicrobial susceptibility testing.

Indexed as

Anti-Bacterial AgentsCephalosporinsCulture MediaDisk Diffusion Antimicrobial TestsCefiderocolDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsPseudomonas aeruginosaReproducibility of ResultsAnti-Bacterial AgentsCefiderocolCephalosporinsCulture MediaAcinetobacter baumanniiantibiotic resistanceCarbapenem-resistant Enterobacteralescefiderocoldisk diffusionmediaPseudomonas aeruginosaquality controlStenotrophomonassusceptibility testing

Identifiers

PMID40130882
PMCPMC12077100

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.